TARO Stock Recent News
TARO LATEST HEADLINES
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.
Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J. , June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd.
MUMBAI, India and NEW YORK , May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024.
MILWAUKEE , May 20, 2024 /PRNewswire/ -- Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun. Click here to learn how to join the https://www.ademilaw.com/case/taro-pharmaceutical-industries-limited or call Guri Ademi toll-free at 866-264-3995.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FULL YEAR RESULTS ON MAY 20, 2024.
Taro (TARO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Taro (TARO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Taro received a $38/share offer from Sun Pharma last month. The deal represents a decent premium to the firm's market value at the time and a 12% premium to my estimate of fair value. Further insights reveal the deal could be valuable to Taro shareholders given all the contributing factors.